Price$12.18+0.02 (+0.16%)
01:30 PM07:45 PM
News · 26 weeks41+250%
2026-01-252026-07-19
Mix2090d
- SEC Filings7(35%)
- Other5(25%)
- Insider3(15%)
- Earnings2(10%)
- Analyst2(10%)
- Leadership1(5%)
Latest news
25 items- SECEyePoint Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- ANALYSTStifel initiated coverage on EyePoint with a new price targetStifel initiated coverage of EyePoint with a rating of Buy and set a new price target of $40.00
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- INSIDERPresident and CEO Duker Jay S. converted options into 16,667 shares and covered exercise/tax liability with 8,059 shares, increasing direct ownership by 873% to 9,594 units (SEC Form 4) (for withholding tax)4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science OfficerWATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer. Dr. Hassan will report directly to Jay S. Duker, M.D., President and CEO of EyePoint, and will serve as a member of the executive leadership team. A globally recognized retina specialist and key opinion leader with more than 35 years of experience, Dr. Hassan will provide strategic guidance across the Company’s portfolio to optimize development, potentia
- ANALYSTCantor Fitzgerald resumed coverage on EyePoint with a new price targetCantor Fitzgerald resumed coverage of EyePoint with a rating of Overweight and set a new price target of $47.00
- INSIDERChief Medical Officer Ribeiro Ramiro sold $73,167 worth of shares (4,875 units at $15.01) and exercised 4,875 shares at a strike of $8.26 (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- SECEyePoint Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 39,700 shares of EyePoint common stock to three new employees. The stock options were granted on June 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- INSIDERChief Financial Officer Elston George converted options into 7,500 shares and covered exercise/tax liability with 3,627 shares, increasing direct ownership by 4% to 91,691 units (SEC Form 4) (withholding obligation)4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Announces Participation at Upcoming Investor ConferencesWATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Stifel 2026 Virtual Ophthalmology ForumForum: Fireside ChatDate: May 26, 2026Time: 9:00 am ET Jefferies Global Healthcare ConferenceForum: Fireside Chat Date: June 3, 2026Time: 4:55 p.m. ETGoldman Sachs 47th Annual Global Healthcare Conference Forum: Fireside ChatDate: June 9, 2026Time: 11:20 a.m. ET A webcast and subsequent archived replay of each fireside chat may be acce
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 158,100 shares of EyePoint common stock to eight new employees. The stock options were granted on May 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical trials – – All active patients in the treatment arm have reached their second DURAVYU dosing visit, with over 35% receiving a third dose – WATERTOWN, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its third scheduled revie
- SECSEC Form 10-Q filed by EyePoint Inc.10-Q - EyePoint, Inc. (0001314102) (Filer)
- SECEyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsPhase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 –Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients enrolled; enrollment completion expected in Q3 2026 –$223 million of cash and investments as of March 31, 2026, with runway into Q4 2027 – WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2026, and highlighted recent corporate developments. "We are e
- PREyePoint to Report First Quarter 2026 Financial Results on May 6, 2026WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/hjmg6gw2. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay
- SECSEC Form DEFA14A filed by EyePoint Inc.DEFA14A - EyePoint, Inc. (0001314102) (Filer)
- SECSEC Form DEF 14A filed by EyePoint Inc.DEF 14A - EyePoint, Inc. (0001314102) (Filer)
- INSIDERSEC Form 4 filed by Ribeiro Ramiro4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 362,500 shares of EyePoint common stock to fourteen new employees. The stock options were granted on April 15, 2026. The grants were approved by the Compensation Committee and made as an inducement ma
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.SCHEDULE 13G/A - EyePoint, Inc. (0001314102) (Subject)
- INSIDERSEC Form 4 filed by Duker Jay S.4 - EyePoint, Inc. (0001314102) (Issuer)
EYPT FAQ
6 questionsWhat does EyePoint Inc. do?
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation...Where does EYPT stock trade?
EyePoint Inc. (EYPT) is listed on NASDAQ.What sector and industry is EYPT in?
EyePoint Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What are analysts saying about EYPT?
EyePoint Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $4000.00 price target on 2026-07-16. Recent price targets range from $1500.00 to $4700.00.What companies are similar to EYPT?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare EYPT side-by-side with any of them on Quantisnow.How can I track EYPT on Quantisnow?
Quantisnow aggregates EyePoint Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EYPT to receive live email and push alerts on every new disclosure.